SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.610
-0.020 (-1.23%)
At close: Jun 6, 2025, 4:00 PM
1.630
+0.020 (1.24%)
After-hours: Jun 6, 2025, 6:04 PM EDT
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
160.64M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SLS News
- 1 day ago - SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts - GlobeNewsWire
- 4 days ago - SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewsWire
- 17 days ago - SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - GlobeNewsWire
- 22 days ago - SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewsWire
- 24 days ago - SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - GlobeNewsWire
- 6 weeks ago - SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire